Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR<sup>−</sup>/HER2<sup>+</sup>breast cancers
Ruth Rodríguez‐Barrueco(Institut d'Investigació Biomédica de Bellvitge), José M. Silva(Icahn School of Medicine at Mount Sinai), Mariano J. Alvarez(Columbia University Irving Medical Center), Kevin Kalinsky(Emory University), Ana Collazo-Lorduy(Icahn School of Medicine at Mount Sinai), Eva Murga-Penas(Cancer Genetics (United States)), Andrea Califano(Johns Hopkins University), Laura Saucedo-Cuevas(Icahn School of Medicine at Mount Sinai), David Llobet‐Navàs(Newcastle University), Carlos Cordon‐Cardo(Icahn School of Medicine at Mount Sinai), Mireia Castillo-Martín(Icahn School of Medicine at Mount Sinai), Jiyang Yu(Columbia University Irving Medical Center), Matthew Maurer(Io Therapeutics (United States)), Preeti Putcha(Cancer Genetics (United States)), Verónica Castro(Cancer Genetics (United States)), Mireia Oliván(Icahn School of Medicine at Mount Sinai)
Cited by 121
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Acid Sphingomyelinase–Deficient Human Lymphoblasts and Mice Are Defective in Radiation-Induced Apoptosis
|Cell|1996|797
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770